Kymera Therapeutics Stock Price Prediction

KYMR Stock  USD 45.98  1.04  2.21%   
As of today, The RSI of Kymera Therapeutics' share price is at 57. This indicates that the stock is in nutural position, most likellhy at or near its resistance level. The main idea of RSI analysis is to track how fast people are buying or selling Kymera Therapeutics, making its price go up or down.

Oversold Vs Overbought

57

 
Oversold
 
Overbought
The successful prediction of Kymera Therapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Kymera Therapeutics and does not consider all of the tangible or intangible factors available from Kymera Therapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with Kymera Therapeutics, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Kymera Therapeutics' stock price prediction:
EPS Estimate Next Quarter
(0.83)
EPS Estimate Current Year
(2.83)
EPS Estimate Next Year
(3.33)
Wall Street Target Price
57.7647
EPS Estimate Current Quarter
(0.84)
Using Kymera Therapeutics hype-based prediction, you can estimate the value of Kymera Therapeutics from the perspective of Kymera Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Kymera Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Kymera because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Kymera Therapeutics after-hype prediction price

    
  USD 45.98  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Kymera Therapeutics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.
Intrinsic
Valuation
LowRealHigh
45.1948.2951.39
Details
17 Analysts
Consensus
LowTargetHigh
51.4456.5362.75
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.78-0.71-0.53
Details

Kymera Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Kymera Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Kymera Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Kymera Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Kymera Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Kymera Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Kymera Therapeutics' historical news coverage. Kymera Therapeutics' after-hype downside and upside margins for the prediction period are 42.88 and 49.08, respectively. We have considered Kymera Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
45.98
45.98
After-hype Price
49.08
Upside
Kymera Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Kymera Therapeutics is based on 3 months time horizon.

Kymera Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Kymera Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kymera Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Kymera Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.03 
3.14
  0.04 
 0.00  
10 Events / Month
11 Events / Month
In about 10 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
45.98
45.98
0.00 
221.13  
Notes

Kymera Therapeutics Hype Timeline

Kymera Therapeutics is now traded for 45.98. The entity has historical hype elasticity of 0.04, and average elasticity to hype of competition of 0.0. Kymera is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is expected to be very small, whereas the daily expected return is now at -0.03%. %. The volatility of related hype on Kymera Therapeutics is about 2104.12%, with the expected price after the next announcement by competition of 45.98. About 99.0% of the company shares are owned by institutional investors. The book value of Kymera Therapeutics was now reported as 13.79. The company has Price/Earnings To Growth (PEG) ratio of 0.64. Kymera Therapeutics recorded a loss per share of 2.34. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be in about 10 days.
Check out Kymera Therapeutics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.

Kymera Therapeutics Related Hype Analysis

Having access to credible news sources related to Kymera Therapeutics' direct competition is more important than ever and may enhance your ability to predict Kymera Therapeutics' future price movements. Getting to know how Kymera Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Kymera Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
FHTXFoghorn Therapeutics(0.47)10 per month 4.44 (0) 8.50 (6.81) 34.64 
STTKShattuck Labs(0.01)10 per month 0.00 (0.19) 6.78 (9.82) 51.03 
GLUEMonte Rosa Therapeutics(0.25)9 per month 3.88  0.07  8.10 (8.18) 102.66 
NRIXNurix Therapeutics 0.02 8 per month 0.00 (0.06) 6.17 (4.73) 22.77 
RVMDRevolution Medicines 1.13 10 per month 2.04  0.13  4.81 (3.24) 10.95 
CCCCC4 Therapeutics(0.35)10 per month 0.00 (0.13) 7.69 (7.98) 23.66 
AGIOAgios Pharm(0.06)9 per month 2.32  0.08  5.24 (4.04) 15.93 
IPSCCentury Therapeutics 0.09 9 per month 0.00 (0.1) 7.44 (8.82) 23.66 
EWTXEdgewise Therapeutics 0.32 10 per month 2.84  0.11  6.65 (4.70) 61.02 
MLYSMineralys Therapeutics, Common 0.14 8 per month 3.42  0.02  6.27 (5.79) 20.98 
CGEMCullinan Oncology LLC 1.25 10 per month 0.00 (0.16) 5.88 (7.24) 17.85 
ELYMEliem Therapeutics 0.25 4 per month 0.00 (0.19) 6.21 (9.35) 34.87 
PRLDPrelude Therapeutics(0.12)7 per month 0.00 (0.38) 5.82 (7.83) 51.12 

Kymera Therapeutics Additional Predictive Modules

Most predictive techniques to examine Kymera price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Kymera using various technical indicators. When you analyze Kymera charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Kymera Therapeutics Predictive Indicators

The successful prediction of Kymera Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Kymera Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Kymera Therapeutics based on analysis of Kymera Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Kymera Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Kymera Therapeutics's related companies.
 2021 2022 2023 2024 (projected)
Current Ratio5.628.844.734.47
Net Debt To EBITDA0.310.340.180.17

Story Coverage note for Kymera Therapeutics

The number of cover stories for Kymera Therapeutics depends on current market conditions and Kymera Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Kymera Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Kymera Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Kymera Therapeutics Short Properties

Kymera Therapeutics' future price predictability will typically decrease when Kymera Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Kymera Therapeutics often depends not only on the future outlook of the potential Kymera Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Kymera Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding58.4 M
Cash And Short Term Investments374.9 M

Additional Tools for Kymera Stock Analysis

When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.